BioAge Labs, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $26.1 million, or $0.58 per share, compared to a net loss of $21.6 million, or $0.60 per share, in the same period last year. For the first half of 2026, the company recorded a net loss of $48.4 million, up from $34.5 million in the first half of 2025. The increase in losses is attributed to higher research and development expenses, which rose 45% to $44.8 million, driven primarily by costs associated with the ongoing development of its lead product candidate, BGE-102.
Collaboration revenue for the second quarter was $2.5 million, slightly up from $2.4 million in the prior year, while total revenue for the first half of 2026 reached $5.2 million, a 35% increase from $3.9 million in the same period of 2025. The revenue growth is largely due to increased efforts under the collaboration agreement with Novartis Pharma AG, which has been a significant contributor to the company's financial performance.
In terms of operational developments, BioAge Labs has made significant strides in its clinical programs. The company initiated the QUELL-CV Phase 2 trial for BGE-102, targeting participants with obesity and elevated cardiovascular risk. Additionally, the company plans to start the QUELL-DME trial for diabetic macular edema in mid-2026. As of June 30, 2026, BioAge Labs had $381.3 million in cash, cash equivalents, and marketable securities, which the company believes will be sufficient to fund operations through 2029.
The company has also seen changes in its capital structure, with an increase in common stock outstanding from 37.4 million shares at the end of 2025 to 45.8 million shares by June 30, 2026. This increase is primarily due to an underwritten public offering completed in January 2026, which raised approximately $107.4 million in net proceeds. BioAge Labs continues to focus on expanding its research and development capabilities and anticipates further increases in operating expenses as it progresses its clinical trials and develops additional product candidates.
Looking ahead, BioAge Labs expects to continue incurring significant losses as it advances its clinical programs and seeks regulatory approvals for its product candidates. The company plans to finance its operations through equity offerings, debt financing, and potential collaborations, while acknowledging the inherent risks and uncertainties associated with the biotechnology industry.
About BioAge Labs, Inc.
BioAge Labs, Inc. is a biopharmaceutical company focused on developing therapies for metabolic diseases by targeting the biology of human aging. Its platform leverages longitudinal human datasets and multi-omic profiling to identify novel targets like NLRP3 and apelin. The company develops oral, brain-penetrant small molecules and collaborates with major pharma firms to create innovative treatments for obesity and age-related conditions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov